Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of a Phase III, Multicenter Study

por Gladman, D, Fleischmann, R, Coteur, G, Woltering, F, Mease, P J
Publicado 2014

Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis

por van der Heijde, D., Deodhar, A., Fleischmann, R., Mease, P. J., Rudwaleit, M., Nurminen, T., Davies, O.
Publicado 2017

Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blin...

por van der Heijde, D, Fleischmann, R, Wollenhaupt, J, Deodhar, A, Kielar, D, Woltering, F, Stach, C, Hoepken, B, Arledge, T, Mease, P J
Publicado 2014

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

por Mease, P J, Fleischmann, R, Deodhar, A A, Wollenhaupt, J, Khraishi, M, Kielar, D, Woltering, F, Stach, C, Hoepken, B, Arledge, T, van der Heijde, D
Publicado 2014

Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross‐sectional analysis from...

por Mease, P.J., Palmer, J.B., Hur, P., Strober, B.E., Lebwohl, M., Karki, C., Reed, G.W., Etzel, C.J., Greenberg, J.D., Helliwell, P. S.
Publicado 2019

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial

por van der Heijde, D, Schiff, M H, Sieper, J, Kivitz, A J, Wong, R L, Kupper, H, Dijkmans, B A C, Mease, P J, Davis, J C
Publicado 2008

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-mar...

por Deodhar, A., Mease, P. J., McInnes, I. B., Baraliakos, X., Reich, K., Blauvelt, A., Leonardi, C., Porter, B., Das Gupta, A., Widmer, A., Pricop, L., Fox, T.
Publicado 2019

Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial

por Sieper, J, Landewé, R, Rudwaleit, M, van der Heijde, D, Dougados, M, Mease, P J, Braun, J, Deodhar, A, Kivitz, A, Walsh, J, Hoepken, B, Nurminen, T, Maksymowych, W P
Publicado 2015

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

por Mease, P J, Ory, P, Sharp, J T, Ritchlin, C T, Van den Bosch, F, Wellborne, F, Birbara, C, Thomson, G T D, Perdok, R J, Medich, J, Wong, R L, Gladman, D D
Publicado 2008

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Ph...

por Landewé, R, Braun, J, Deodhar, A, Dougados, M, Maksymowych, W P, Mease, P J, Reveille, J D, Rudwaleit, M, van der Heijde, D, Stach, C, Hoepken, B, Fichtner, A, Coteur, G, de Longueville, M, Sieper, J
Publicado 2014

Treatment recommendations for psoriatic arthritis

por Ritchlin, C T, Kavanaugh, A, Gladman, D D, Mease, P J, Helliwell, P, Boehncke, W-H, de Vlam, K, Fiorentino, D, FitzGerald, O, Gottlieb, A B, McHugh, N J, Nash, P, Qureshi, A A, Soriano, E R, Taylor, W J
Publicado 2009